// App-Quantinova.ai

3083 : AGI-134, a fully synthetic -Gal-based cancer immunotherapy: Synergy with an anti-PD-1 antibody and pre-clinical pharmacokinetic and toxicity profiles.

Researchers

Presenter

  • Sascha A. Kristian

Principal Investigators

  • Stephen M. Shaw

  • Kim Wigglesworth

  • Jenny Middleton

  • Melanie S. Glossop

  • Giles Francis Whalen

  • Robert Old

  • Uri Galili

  • Mike Westby

  • Chris Pickford

Medical Centers

  • Agalimmune Ltd., Sandwich, United Kingdom

  • University of Massachusetts, Worcester, Worcester, MA

  • Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

  • University of Massachusetts Medical School, Worcester, MA

  • Agalimmune Ltd., Sandwich, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • Agalimmune Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved